(Corrects to show that Valeant based in Laval, Quebec, not
July 31 Valeant Pharmaceuticals International
Inc on Thursday said it remains on the hunt for other
companies, including makers of innovative contact lenses, as it
presses on with efforts to take over Botox-maker Allergan Inc
On a conference call with investors, Valeant Chief Executive
Officer Michael Pearson said the company will not be content to
remain the No. 4 global player in the contact lens industry.
Valeant officials said Allergan shareholders would profit
more through a merger with Laval, Quebec-based Valeant than
remaining a standalone company.
The company said Allergan shareholders would receive about
twice as much cash earnings per share - meaning profits adjusted
for one-time items - in 2016 with a merged company, than if
Allergan were to remain independent.
(Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe)